Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting.
ICR
Immune checkpoint
Immune favorable
Prognostic
lncRNA
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
30 09 2022
30 09 2022
Historique:
received:
16
07
2022
accepted:
19
09
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
Advances in our understanding of the tumor microenvironment have radically changed the cancer field, highlighting the emerging need for biomarkers of an active, favorable tumor immune phenotype to aid treatment stratification and clinical prognostication. Numerous immune-related gene signatures have been defined; however, their prognostic value is often limited to one or few cancer types. Moreover, the area of non-coding RNA as biomarkers remains largely unexplored although their number and biological roles are rapidly expanding. We developed a multi-step process to identify immune-related long non-coding RNA signatures with prognostic connotation in multiple TCGA solid cancer datasets. Using the breast cancer dataset as a discovery cohort we found 2988 differentially expressed lncRNAs between immune favorable and unfavorable tumors, as defined by the immunologic constant of rejection (ICR) gene signature. Mapping of the lncRNAs to a coding-non-coding network identified 127 proxy protein-coding genes that are enriched in immune-related diseases and functions. Next, we defined two distinct 20-lncRNA prognostic signatures that show a stronger effect on overall survival than the ICR signature in multiple solid cancers. Furthermore, we found a 3 lncRNA signature that demonstrated prognostic significance across 5 solid cancer types with a stronger association with clinical outcome than ICR. Moreover, this 3 lncRNA signature showed additional prognostic significance in uterine corpus endometrial carcinoma and cervical squamous cell carcinoma and endocervical adenocarcinoma as compared to ICR. We identified an immune-related 3-lncRNA signature with prognostic connotation in multiple solid cancer types which performed equally well and in some cases better than the 20-gene ICR signature, indicating that it could be used as a minimal informative signature for clinical implementation.
Sections du résumé
BACKGROUND
Advances in our understanding of the tumor microenvironment have radically changed the cancer field, highlighting the emerging need for biomarkers of an active, favorable tumor immune phenotype to aid treatment stratification and clinical prognostication. Numerous immune-related gene signatures have been defined; however, their prognostic value is often limited to one or few cancer types. Moreover, the area of non-coding RNA as biomarkers remains largely unexplored although their number and biological roles are rapidly expanding.
METHODS
We developed a multi-step process to identify immune-related long non-coding RNA signatures with prognostic connotation in multiple TCGA solid cancer datasets.
RESULTS
Using the breast cancer dataset as a discovery cohort we found 2988 differentially expressed lncRNAs between immune favorable and unfavorable tumors, as defined by the immunologic constant of rejection (ICR) gene signature. Mapping of the lncRNAs to a coding-non-coding network identified 127 proxy protein-coding genes that are enriched in immune-related diseases and functions. Next, we defined two distinct 20-lncRNA prognostic signatures that show a stronger effect on overall survival than the ICR signature in multiple solid cancers. Furthermore, we found a 3 lncRNA signature that demonstrated prognostic significance across 5 solid cancer types with a stronger association with clinical outcome than ICR. Moreover, this 3 lncRNA signature showed additional prognostic significance in uterine corpus endometrial carcinoma and cervical squamous cell carcinoma and endocervical adenocarcinoma as compared to ICR.
CONCLUSION
We identified an immune-related 3-lncRNA signature with prognostic connotation in multiple solid cancer types which performed equally well and in some cases better than the 20-gene ICR signature, indicating that it could be used as a minimal informative signature for clinical implementation.
Identifiants
pubmed: 36180904
doi: 10.1186/s12967-022-03654-7
pii: 10.1186/s12967-022-03654-7
pmc: PMC9523969
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
442Informations de copyright
© 2022. The Author(s).
Références
BMC Genomics. 2022 May 7;23(1):351
pubmed: 35525921
J Transl Med. 2020 Nov 7;18(1):416
pubmed: 33160384
Int J Biol Macromol. 2018 Oct 15;118(Pt A):24-30
pubmed: 29886172
Mol Oncol. 2019 Jan;13(1):61-73
pubmed: 30499165
Nat Immunol. 2019 Jul;20(7):835-851
pubmed: 31160797
Nat Commun. 2022 Feb 10;13(1):816
pubmed: 35145098
Front Oncol. 2020 Nov 26;10:598626
pubmed: 33324565
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 33979427
Onco Targets Ther. 2021 Jan 13;14:393-402
pubmed: 33469315
Front Pharmacol. 2020 Aug 19;11:1289
pubmed: 32973519
J Cell Biochem. 2020 Feb;121(2):1823-1833
pubmed: 31680313
NPJ Breast Cancer. 2021 Feb 8;7(1):10
pubmed: 33558495
Front Mol Biosci. 2021 Jul 13;8:689224
pubmed: 34327215
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Bioengineered. 2021 Dec;12(1):6083-6095
pubmed: 34516330
JAMA Netw Open. 2020 Apr 1;3(4):e202149
pubmed: 32259264
J Cell Mol Med. 2020 Nov;24(21):12444-12456
pubmed: 32967061
Oncoimmunology. 2017 Feb 6;6(2):e1253654
pubmed: 28344865
Genes (Basel). 2018 Jan 05;9(1):
pubmed: 29303984
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35017155
Front Immunol. 2019 Dec 17;10:2965
pubmed: 31921205
Sci Rep. 2017 Apr 20;7:46566
pubmed: 28425476
J Transl Med. 2020 Nov 23;18(1):442
pubmed: 33225954
Semin Cancer Biol. 2020 Oct;65:65-79
pubmed: 31733291
J Clin Invest. 2017 Mar 1;127(3):772-779
pubmed: 28248202
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32376723
Genomics. 2020 May;112(3):2640-2646
pubmed: 32087243
J Cell Physiol. 2020 Dec;235(12):9304-9316
pubmed: 32330311
Cancer Cell Int. 2021 Dec 20;21(1):691
pubmed: 34930244
Cancer Med. 2019 Jan;8(1):289-304
pubmed: 30516029
Nucleic Acids Res. 2009 Jan;37(Database issue):D623-8
pubmed: 18940869
Neuro Oncol. 2015 Feb;17(2):171-3
pubmed: 25523594
Nucleic Acids Res. 2011 Jan;39(Database issue):D712-7
pubmed: 21071422
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Front Oncol. 2017 Apr 12;7:68
pubmed: 28447025
BMC Cancer. 2019 Dec 3;19(1):1171
pubmed: 31795964
Front Genet. 2021 Jan 21;11:634195
pubmed: 33584821
Front Cell Dev Biol. 2021 Oct 13;9:739583
pubmed: 34722522
Front Genet. 2020 Jul 07;11:680
pubmed: 32733537
Genome Biol. 2015 Mar 31;16:64
pubmed: 25853550
Front Oncol. 2019 Nov 28;9:1292
pubmed: 31850199
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32041817
Curr Opin Oncol. 2015 Nov;27(6):433-44
pubmed: 26418235
Oncol Rep. 2021 Jul;46(1):
pubmed: 34036383
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
Bioengineered. 2021 Dec;12(1):2311-2325
pubmed: 34167440
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cancer Res. 2019 Dec 15;79(24):6238-6246
pubmed: 31641033
Front Genet. 2020 Jul 24;11:718
pubmed: 32793280
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Cancer Immunol Res. 2020 Jul;8(7):937-951
pubmed: 32321773
Front Oncol. 2020 Oct 30;10:550987
pubmed: 33194608
Genome Biol. 2017 Oct 31;18(1):206
pubmed: 29084573
Br J Cancer. 2018 Nov;119(11):1383-1391
pubmed: 30353048
Bioengineered. 2022 Mar;13(3):5407-5420
pubmed: 35176937
Cell Death Dis. 2019 Aug 8;10(8):599
pubmed: 31395854
Nat Commun. 2013;4:2612
pubmed: 24113773
Front Immunol. 2020 Jun 30;11:1218
pubmed: 32714316
Front Bioeng Biotechnol. 2020 Jul 13;8:702
pubmed: 32754579
Hepatol Int. 2021 Apr;15(2):444-458
pubmed: 33219943